A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers
Wound Heal
About this trial
This is an interventional treatment trial for Wound Heal
Eligibility Criteria
Inclusion Criteria: Has signed informed consent Is above 18 years of age and has full legal capacity Has venous leg ulcer (C6 of the CEAP classification) with a duration longer than 8 weeks but no longer than 5 years Has acceptance of compression bandages Has a wound at risk of infection based on WAR (wounds at risk of infection) score with score of ≥3 points OR has at least three of the following clinical signs of bacterial contamination based on the Therapeutic index for local infections (TILI) score: Erythema to surrounding skin Heat Oedema, induration or swelling Spontaneous pain or pressure pain Stalled wound healing Increase and/or change of color of exudate Increase and/or change of smell of exudate Has wound area of min 2x2 cm and max 10x10 cm Has wound with depth of max 2 cm Has wound with medium to high level of exudate (but should not require more than 1 dressing change/day) Has ankle-brachial pressure (ABI) ≥0.8 AND, for patients with diabetes mellitus, additional biphasic Doppler signal up to the ankle Ability (assessed by the investigator) and willingness to adhere to a 1-month intervention period For patients with diabetes, has HbA1c ≤ 10%/≤ 86 mmol/mol, measured within the last 3 months prior to inclusion Should be able to follow the study protocol with the prescribed cleansing product (NaCl) and dressing Exclusion Criteria: Is pregnant or breastfeeding Has wounds with exposed tendons, bones, fistulas. Or wounds with cavity, undermined or tunnelling Has infection requiring antibiotics (also for other reasons than wound infection) OR has received antibiotics within the last 2 weeks before inclusion Has been receiving the following medical treatment within the last 4 weeks: corticoids, immunosuppression, immunomodulating medication or cytostatic Has a systemic hematological disease Has renal insufficiency requiring dialysis Has advanced heart failure NYHA III/IV Has a psychiatric illness that inhibits compliance with the study protocol Has severe congenital immunodeficiency such agammaglobulinemia, severe combined immunodeficiency (SCID) Has allergy towards silver or other dressing ingredients (including compression therapy) Has wound with > 50% necrotic tissue Treatment of wound with an anti-microbial wound dressing within the last 2 weeks
Sites / Locations
- Avail Primary Care Clinic
- Three Rivers Wound and Research Center
- Detroit foot and ankle SpecialistsRecruiting
- Serena Group
- Dermato-Venerologisk Afd
- Nordsjællands Hospital Hillerød
- Sygehus Lillebælt Kolding
- Katholisches Klinikum Bochum
- Krankenhaus Buchholz und Winsen gemeinnüzige GmbH
- Universitätsklinikum ErlangenRecruiting
- Universitätsklinikum Giessen und Marburg GmbHRecruiting
- WoundConsulting GmbH Uniklinik Halle/Saale
- Städtisches Klinikum Karlsruhe GmbH
- Krankenhaus Reinbek, St Adolf-Stift GmbHRecruiting
- Klinik und Poliklinik für Dermatologie and Venerologie
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Biatain Ag
Cutimed Siltec Sorbact